Resources

Pain is a prevalent and often severe symptom that impacts global health status for almost every patient with a rheumatic disease. In response to the Guideline for opioid therapy and chronic non-cancer pain published in the Canadian Medical Association Journal...

The medical management of juvenile idiopathic arthritis (JIA) and its complications has undergone significant changes in the last decade, a result largely of the introduction of biologics and increased availability of expertise in the diagnosis and management of rheumatic diseases […]

Methotrexate remains an important therapeutic agent in Rheumatology, for Rheumatoid arthritis and other systemic and auto-immune diseases. Its prescription and subsequent use is often challenged by mis-information at the dispensing levels, often finding the origin of the mis-information in various […]

Algorithm for the Management of High Dose (150 mg daily) Diclofenac Usage in Chronic Pain Patients.

This metanalysis deals with the risks of cardiovascular and gastrointestinal events and deaths with the use of high-dose COX-2 inhibitors, diclofenac, and naproxen compared to placebo.. Reviewed by Therapeutics Committee in November 2021 and no changes made.

The Canadian Rheumatology Association (CRA) and the Spondyloarthritis Research Consortium of Canada (SPARCC) have collaborated to update the recommendations for the management of spondyloarthritis (SpA)...

The CRA has developed 2011/2012 recommendations for the pharmacological management of RA that take into consideration Canada’s current healthcare system. The recommendations address treatment questions identified from a national needs assessment survey of Canadian rheumatology professionals and are published in […]